Acorda Therapeutics, Inc. (NASDAQ: ACOR) had its price target raised by analysts at Cowen Inc from $5.00 to $35.00.
Last acorda therapeutics, inc earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
| Impact snapshot | Event time: | ACOR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACOR alerts
ACOR alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
ACOR
News
- Acorda Therapeutics to sell Inbrija manufacturing operations for $80M, reduces headcount by 16%, shares up 65% [Seeking Alpha]Seeking Alpha
- Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into “At The Market” Offering AgreementBusiness Wire
- Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care ConferenceBusiness Wire
- Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual ConferenceBusiness Wire
- Acorda Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACOR/price-target/">NASDAQ: ACOR</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $0.75 price MarketBeat
- More
ACOR
SEC Filings
- 1/20/21 - Form 8-K
- 1/13/21 - Form 424B5
- 1/13/21 - Form 8-K
- ACOR's page on the SEC website
- More